A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Endometrial Cancer
- Endometrial Cancer Recurrent
- Endometrial Carcinoma
- Endometrial Carcinoma, Recurrent
- Endometrial Carcinosarcoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03015129
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Vicky Makker, MD Memorial Sloan Kettering Cancer Center
Get Well Soon